Retatrutide vs Tirzepatide vs Semaglutide: Who Really Wins?
Retatrutide out-lost Zepbound and Wegovy in phase 3. But it has never faced tirzepatide head to head, it is not approved, and one side effect rarely makes the hype posts.
TL;DR
- Retatrutide vs tirzepatide: in trials, retatrutide produced more weight loss. People on the top 12 mg dose lost 25.0% of body weight at 80 weeks counting everyone who started, versus 20.2% for tirzepatide and 13.7% for semaglutide in a separate head-to-head trial.
- The difference is a third receptor. Retatrutide hits GLP-1, GIP and glucagon. Tirzepatide hits two. Semaglutide hits one.
- Reality check: retatrutide has never been tested head to head against tirzepatide, and it is not FDA approved. Lilly plans to file in Q1 2027.
- Anything sold as retatrutide today is an unapproved product. And the trials flagged a side effect worth knowing about: skin tingling called dysesthesia.
Retatrutide isn't approved, isn't in pharmacies, and is already the most searched of the unapproved peptides promoted online, according to Google search data cited by Public Citizen. Some people are injecting gray-market vials of it right now.
So is the "triple G" shot really better than tirzepatide (Zepbound) and semaglutide (Wegovy)? On raw weight loss, the trial numbers say probably. On everything else, the answer is messier.
The detail that matters most is a side effect the hype posts barely mention. It's in the risks section.
Retatrutide vs tirzepatide vs semaglutide: how does each one work?
All three copy hormones your gut already makes after a meal. The difference is how many of those hormone "locks" each drug turns.
Semaglutide: one receptor (GLP-1)
GLP-1 tells your brain you're full, slows how fast your stomach empties, and helps your pancreas release insulin when blood sugar rises. Semaglutide is a long-lasting copy of it.
Tirzepatide: two receptors (GLP-1 + GIP)
Tirzepatide adds GIP, a second gut hormone involved in insulin release and fat storage. The two signals together push appetite and weight down further than GLP-1 alone.
Retatrutide: three receptors (GLP-1 + GIP + glucagon)
Here's the twist. Glucagon normally raises blood sugar, which sounds like the opposite of what you want. But glucagon also tells the liver to burn fat and appears to raise energy expenditure. Pair it with GLP-1 and GIP, which pull blood sugar down, and you get appetite suppression plus extra calorie burn. Researchers nicknamed it the "triple G" agonist.
Semaglutide turns down hunger. Tirzepatide turns it down harder. Retatrutide also turns up the furnace.
How much weight do people actually lose?
| Drug | Receptors | Key trial (top dose) | Average weight loss | Status |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | SURMOUNT-5, up to 2.4 mg weekly, 72 weeks | 13.7% | FDA approved for obesity |
| Tirzepatide (Zepbound) | GLP-1, GIP | SURMOUNT-5, up to 15 mg weekly, 72 weeks | 20.2% | FDA approved for obesity |
| Retatrutide | GLP-1, GIP, glucagon | TRIUMPH-1, 12 mg weekly, 80 weeks | 25.0% (28.3% for people who stayed on it) | Investigational. FDA filing planned Q1 2027 |
Two numbers for retatrutide is not a typo. Lilly's May headline was 28.3%, which estimates what happens if everyone stays on the drug. The peer-reviewed paper leads with 25.0%, which counts everyone who started, including people who quit. The second number is the fairer one to compare, and it is still the biggest of the three.
A few more TRIUMPH-1 numbers, as Lilly reported them for people who stayed on treatment (human, phase 3, placebo-controlled):
- 45.3% of people on 12 mg lost at least 30% of their body weight, a level usually linked to bariatric surgery.
- Even the lowest dose tested, 4 mg, averaged 19.0%, not far from tirzepatide's top-dose result.
- In an extension for people with a BMI of 35 or more, those who stayed on 12 mg reached 30.3% at 104 weeks.
In people with type 2 diabetes, who usually lose less, Lilly reported up to 20.8% at 80 weeks in TRIUMPH-2, again for people who stayed on treatment.
Want the full safety rundown? Get the free Peptide Research & Safety Handbook when you join Peptide Maven. One email a week, zero hype.
What does the evidence actually show?
| Claim | Best evidence | Tier | Verdict |
|---|---|---|---|
| Tirzepatide beats semaglutide for weight loss | SURMOUNT-5, a 751-person head-to-head randomized trial | Human trials (head to head) | Yes |
| Retatrutide beats tirzepatide for weight loss | Separate phase 3 trials, no head-to-head study | Human trials, indirect comparison | Probably, not proven |
| Retatrutide clears liver fat | Phase 2 subgroup in people with fatty liver | Small or early human studies | Promising |
| Retatrutide protects the heart | TRIUMPH-3 saw fewer heart events than expected in both groups | Human trials, not powered for this | Unknown |
| Gray-market "retatrutide" works like the real thing | No controlled data. Contents of unapproved products are unverified | Anecdote only | Unknown, and risky |
The liver result deserves a note. In a phase 2 subgroup of people who started with at least 10% liver fat, the 8 mg and 12 mg doses brought liver fat back to normal levels in roughly 80% of them by 24 weeks and around 90% by 48 weeks. That's a big signal, but it came from a subgroup of a mid-stage trial, so treat it as early human data.
What are the side effects and risks?
The usual GI stuff, turned up
All three drugs cause nausea, diarrhea, constipation and vomiting, mostly while the dose is being raised. In TRIUMPH-1, nausea hit 42.4% of people on retatrutide 12 mg versus 14.8% on placebo. For context, about 44% of people on tirzepatide and on semaglutide reported nausea in SURMOUNT-5.
The one nobody talks about: dysesthesia
Dysesthesia means abnormal skin sensations like tingling, burning or sensitivity. In TRIUMPH-1 it showed up in 12.5% of people on 12 mg versus 0.9% on placebo. Lilly says most cases were mild to moderate and most resolved during treatment. Still, Lilly reports it separately from the usual stomach side effects, and it climbed with dose (5.1% at 4 mg), which is one reason the lower doses may matter as much as the headline dose.
More people quit at the top dose
11.3% of people on retatrutide 12 mg stopped because of side effects, versus 4.9% on placebo. At 4 mg, the rate was 4.1%. Urinary tract infections were also slightly more common on the drug.
The gray-market problem
Lilly says retatrutide is legally available only to people in its clinical trials. Public Citizen reported that the FDA has sent 14 warning letters to retatrutide sellers since 2024 and that the FDA's adverse event system listed 14 hospitalizations connected to retatrutide as of June 2026. Those reports don't prove the drug caused the harm, and nobody can verify what was actually in those vials. That's the point.
The trial drug and the vial on your feed are not the same product. Only one of them has data.
The skeptic's case: is retatrutide really better?
Cross-trial comparisons lie a little. TRIUMPH-1 ran 80 weeks. SURMOUNT-5 ran 72. Different people enrolled, with different starting weights. The only true head-to-head here is tirzepatide versus semaglutide, and even that trial was open label because the pens were labeled. Until retatrutide faces tirzepatide in the same trial, "25% beats 20%" is an educated guess, not a verdict.
Bigger isn't always better. For many people, the goal isn't losing 30% of their body weight. Tirzepatide already got the average trial participant to about 20%, it's approved, and it has years of real-world use. Retatrutide's extra loss comes with more dropouts and a new side effect to watch.
Everyone funding the data sells the drugs. Lilly funded TRIUMPH and SURMOUNT-5 and makes both tirzepatide and retatrutide. Several of these results are now peer reviewed, but independent replication will matter.
Our take: retatrutide posted bigger phase 3 weight loss than either approved drug, by a real margin. It is also not available, not approved, and not yet compared directly. Worth watching closely. Not worth a mystery vial.
So which one wins?
- Most weight loss in trials: retatrutide.
- Strongest head-to-head data you can legally get today: tirzepatide, which beat semaglutide head to head.
- Longest track record: semaglutide.
- Fatty liver: retatrutide looks strongest, based on early human data.
- Fewest unknowns: the two approved drugs.
Curious how GLP-1 drugs fit into the bigger peptide picture? Start with our explainer on how weight-loss peptides work, plus their benefits and risks.
FAQ
Is retatrutide FDA approved?
No. Retatrutide is investigational. Lilly says it plans to submit it to the FDA in Q1 2027, and that until then it is legally available only to people in Lilly's clinical trials.
Is retatrutide stronger than tirzepatide?
In separate trials, yes. Retatrutide 12 mg averaged 25.0% weight loss at 80 weeks counting everyone who started, while tirzepatide 15 mg averaged 20.2% at 72 weeks in SURMOUNT-5. The two have never been compared in the same trial, so the gap is an estimate.
What is the difference between retatrutide, tirzepatide and semaglutide?
The number of hormone receptors each one activates. Semaglutide activates GLP-1. Tirzepatide activates GLP-1 and GIP. Retatrutide activates GLP-1, GIP and glucagon, and the glucagon piece appears to add fat burning, especially in the liver.
What is dysesthesia on retatrutide?
It is abnormal skin sensation, such as tingling or burning. It was reported in 12.5% of people on retatrutide 12 mg versus 0.9% on placebo in TRIUMPH-1. Lilly reported most cases were mild to moderate and most resolved during treatment.
Why are there two different weight loss numbers for retatrutide?
They answer different questions. The 28.3% figure estimates the result if everyone stayed on the drug. The 25.0% figure, the primary result in the published paper, counts everyone who started, including people who stopped.
The Bottom Line
Retatrutide posted the biggest phase 3 weight loss of these three drugs, and the glucagon mechanism gives it a real scientific reason to beat tirzepatide. But it has not been tested against tirzepatide directly, it brings a new side effect in dysesthesia, and it is not approved. If you need a GLP-1 drug today, the two approved options have the data. If you're waiting for retatrutide, wait for the real one.
For a look at what GLP-1 may do beyond the scale, read our deep dive on GLP-1 and the brain, or compare options in peptides for fat loss.
Sources: Eli Lilly, TRIUMPH-1 topline results (May 21, 2026); Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results (July 23, 2026); Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist, critical review (2026); Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, Phase 2 (NEJM, 2023); The Hospitalist (Medscape), Triple G Agonist Hits New Weight Loss Heights; Weill Cornell Medicine, Head-to-Head Trial Compares Weight Loss Drugs (SURMOUNT-5); Eli Lilly, SURMOUNT-5 results published in NEJM; Public Citizen, The Miracle Drug and the Peptide Craze Breaking the FDA (June 2026)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this website is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional.